Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ออลบานี นิวยอร์ก, March 20, 2026 (GLOBE NEWSWIRE) -- Curia องค์กรชั้นนำด้านการรับจ้างวิจัย พัฒนา และผลิต (Contract Research, Development and Manufacturing Organization, CDMO)...
-
미국 뉴욕주 올버니, March 20, 2026 (GLOBE NEWSWIRE) -- 글로벌 위탁연구·개발·생산(CDMO) 기업인 Curia가 영국 글래스고에 위치한 무균 의약품 생산 시설의 확장 진행 상황과 함께, 자사의 세포주 개발 플랫폼 고도화에 대한 성과를 오늘 발표했다. 영국 글래스고 사이트는 제형 개발, 동결건조(lyophilization)...
-
ニューヨーク州オールバニ発 , March 20, 2026 (GLOBE NEWSWIRE) -- 研究開発・製造業務受託機関 (CDMO) のリーダーであるキュリア (Curia) は本日、英国グラスゴーにある無菌製剤施設の拡張および、同社独自の細胞株開発プラットフォームの強化に関する進捗状況を発表した。 ...
-
ALBANY, New York, March 20, 2026 (GLOBE NEWSWIRE) -- Curia, perusahaan penelitian, pengembangan, dan manufaktur berbasis kontrak (CDMO) terkemuka, hari ini mengumumkan kemajuan dalam ekspansi di...
-
Exton, PA, March 19, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights’ Q1 2026 update of RealTime Dynamix™: Multiple Myeloma findings point to a clear inflection in treatment strategy, as physicians...
-
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”)...
-
TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice...
-
Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à...
-
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as...
-
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the...